Bloomberg News is not one of the news organizations we review on a regular basis.
If we did, this story – “Diabetes May Be Reversed by Long-Used Vaccine for TB” – would not get a good score.
Troublesome:
“We are always hoping for an immune cure for diabetes,” Wittlin tells WebMD. “But so far all the immune studies that looked promising in early human studies have failed in large-scale trials.”
Wittlin notes that previous efforts to treat or prevent type 1 diabetes with BCG vaccine have failed.”
“I’m concerned about increasing the levels of TNF in the body,” he added. “They’re saying that only the insulin-secreting cells are affected, but what are the long-term effects if it’s given repeatedly? What about the growing cells in children, because if it works it would be used in children.”
Opinions on other issues in news, journals, PR, advertising, marketing
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments (16)
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Skeptical
August 10, 2012 at 5:59 pmThank you. I would have loved to have read your analysis of the full text Gary Schwitzer. I have little to no confidence in this research. And it’s costing millions. http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0041756
Zman
August 11, 2012 at 2:34 amIt appears sir that this article was posted in many more sites than just Bloomberg. And the head researcher is far from some quack. I have read about her research throughout the last few years with great interest. Including her struggles with financing. It also appears in Italy and other places around the world they are coming up with similar results. I’m glad big pharma is staying away from this and it is being funded privately. Who would want a “cure” that is so cheap and easily accessible? Where’s the money in that?
Gary Schwitzer
August 13, 2012 at 10:25 amZman,
First, we wish all commenters would use their real name. We use ours. Why can’t we know who you are?
Second, not sure what your point is about “this article was posted in many more sites than just Bloomberg.” We commented on a story written by and published by Bloomberg. We also showed how other news organizations did a better job.
Third, just to be clear, we didn’t say anything about anyone being a “quack.” You used that term. We didn’t.
Zman
August 11, 2012 at 2:50 amAlso sir you should have put all of Dr. Wittlins comments rather than just take the parts you wanted to post, I especially enjoyed the part where he said “but the devil maybe in the details” Dr. Faustman hopes so too as do many others. Whether its successful or not I admire the fight. My 6yr old daughter and I appreciate all who are working towards finding a cure to type 1 diabetes.
David Evans
August 13, 2012 at 8:43 pmI’m fed up with stories about medications or vaccines or devices eliminating life-long insulin shots. As a now-retired biochemist and a Type 1 Diabetic for four decades, I wish promoters of the “alternatives” would do statistically-valid studies of, e.g., BCG, or examine the long-term cost and inconvenience to the diabetic person. Three is not a statistically significant sample size, compared with the 200000 Type 1 diabetics just here in Australia (population 22 million). Surgically-implanted pumps failed fatally too often back in the 1980s. Ultrasonic “pills” that exude Insulin to the gut wall will not work nearly as reliably and consistently as subcutaneous injection any time soon, and cost $30 per single-use device (PR handout reproduced in New Scientist magazine, 23 June 2012, p 20). I’ve been doing pain-free injections 19 times out of 20 for 30 years now. Getting drops of blood to test Blood Glucose levels without pain or calluses on fingertips is a vastly higher priority for me.
Mike - Ohio
August 15, 2012 at 10:42 amMy take on this is very simple. There are 2 opinions on this topic, the one I share which is great hope and a firm belief in what Dr. Faustman is doing on the way to a cure. And that of those somehow tied into the Pharmacy industry. NO ONE in the Pharm industry wants this to succeed as there is absolutely NO money in it for them. Many people have been making tons of money off of us T1D and are doing, and will be doing, everything in their power to stop or hinder this research. Our numbers are strong and our fundraising will continue to help push the good Dr. through all the red tape that will surely be placed in front of her by the greed of our counterparts in the Pharm industry.
-“Money over lives” will not win this battle
Gary Schwitzer
August 16, 2012 at 10:15 amMike,
Thanks for your note.
Let me me emphasize that my original post was about the quality of journalism involved.
Whether it’s a story about diabetes or heart disease or cancer or Alzheimer’s disease, if the story includes predictions of seismic change after results in just two people while including no independent expert perspective, we’re going to criticize it.
Mike - Ohio
August 15, 2012 at 10:42 amMy take on this is very simple. There are 2 opinions on this topic, the one I share which is great hope and a firm belief in what Dr. Faustman is doing on the way to a cure. And that of those somehow tied into the Pharmacy industry. NO ONE in the Pharm industry wants this to succeed as there is absolutely NO money in it for them. Many people have been making tons of money off of us T1D and are doing, and will be doing, everything in their power to stop or hinder this research. Our numbers are strong and our fundraising will continue to help push the good Dr. through all the red tape that will surely be placed in front of her by the greed of our counterparts in the Pharm industry.
-“Money over lives” will not win this battle
Zman
August 16, 2012 at 3:13 pmFirst and foremost Mr. Schwitzer, I would like to apologize for my remarks. It was another very late night of trying to get my 6 year old daughters levels back up. It just wasn’t happening, and for some reason the skeptical post after your story hit a nerve. I do applaud you for pointing out the one sidedness of the article. My name is Ray Zamora Jr. (zmaninc04@hotmail.com) and my daughter Juliana has been a type 1 diabetic for nearly 3 years now. I am not naive enough to believe it is a cure. At best if bcg is successful in larger studies and the raised TNF levels are safe for people, it would only be a treatment and not a cure. But it would bring some normality back into my daughters life. Maybe even be able to enjoy her childhood a little. She’s had to grow up way to early as have so many other children. We have cured thousands of mice from T1 diabetes and every time the scientists speak about it. The same phrase always comes out and it’s along the lines of “this is still very many years away from even being considered for people.” if it were something like H1N1, The government would have intervened no matter what the cost. And as much as I hate to say it “big pharma” can see those cases rising and can count on each one those diagnosed to be they’re own ATM machine for that persons lifetime. Personally though, if one of those companies were to come up with a cure. I would buy pretty much anything they offer because that companies name would be a gold standard, for they would have come up with a cure for a terrible disease. You couldn’t get any better advertising than that. To be able to say we cured T1 diabetes. Once again sir, my apologies. Im just a tired dad who wants nothing more than for all of those affected by type 1 diabetes to be rid of it.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like